coadministered cagrilintide and semaglutide in adults with overweight or obesity New the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk Efficacy and safety of co-administered

### Funding Statement No funding ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained

A single agonist that makes you feel full longer and slows digestion whilst drowning out food noise

But only these specific types of exercise will strengthen your skeleton

The Risks: Unknown ingredients and contamination Incorrect dosages and life-threatening side effects No regulatory oversight or safety data Why This Is Critical: Patients are bypassing pharmacies and getting injections from sketchy online vendors This undermines real GLP1 therapies and can lead to serious harm As healthcare professionals, we must: Ask patients about the source of their medications Report adverse reactions to MedWatch Educate our patients about safe access and real prescriptions Lets advocate for ethical prescribing and responsible patient care in the GLP1 era

Creatine Hydration Powder GLP-1-associated weight loss includes lean mass

How women are finally getting rid of meno belly and finding success getting back to their happy weight after menopausal weight gain.